[1]
|
Shirazi, F.M., Mirzaei, R., Nakhaee, S., Nejatian, A., Ghafari, S. and Mehrpour, O. (2022) Repurposing the Drug, Ivermectin, in COVID-19: Toxicological Points of View. European Journal of Medical Research, 27, Article No. 21.
https://doi.org/10.1186/s40001-022-00645-8
|
[2]
|
González Canga, A., Sahagún Prieto, A.M., Diez Liébana, M.J., Martínez, N.F., Vega, M.S. and Garcia Vieitez, J.J. (2008) The Pharmacokinetics and Interactions of Ivermectin In Humans—A Mini-Review. The AAPS Journal, 10, 42-46. https://doi.org/10.1208/s12248-007-9000-9
|
[3]
|
Molento, M.B. (2020) COVID-19 and the Rush for Self-Medication and Self-Dosing with Ivermectin: A Word of Caution. One Health, 10, Article ID: 100148. https://doi.org/10.1016/j.onehlt.2020.100148
|
[4]
|
Formiga, F.R., Leblanc, R., de Souza Reboucas, J., Farias, L.P., de Oliveira, R.N. and Pena, L. (2021) Ivermectin: An Award-Winning Drug with Expected Antiviral Activity against COVID-19. Journal of Controlled Release, 329, 758-761.
https://doi.org/10.1016/j.jconrel.2020.10.009
|
[5]
|
Ahmed, S., Karim, M.M., Ross, A.G., Hossain, M.S., Clemens, J.D., Sumiya, M.K., Phru, C.S., Rahman, M., Zaman, K., Somani, J., et al. (2021) A Five-Day Course of Ivermectin for the Treatment of COVID-19 May Reduce the Duration of Illness. International Journal of Infectious Diseases, 103, 214-216. https://doi.org/10.1016/j.ijid.2020.11.191
|
[6]
|
Wolfrom, E., Chêne, G., Lejoly-Boisseau, H., Beylot, C., Geniaux, M. and Taïeb, A. (1996) [Chronic Urticaria and Toxocaracanis Infection. A Case-Control Study]. Annales de Dermatologie et de Vénéréologie, 123, 240-246. (In French)
|
[7]
|
Jermain, B., Hanafin, P.O., Cao, Y., Lifschitz, A., Lanusse, C. and Rao, G.G. (2020) Development of a Minimal Physiologi-cally-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing. Journal of Pharmaceutical Sciences, 109, 3574-3578.
https://doi.org/10.1016/j.xphs.2020.08.024
|
[8]
|
Caly, L., Druce, J.D., Catton, M.G., Jans, D.A. and Wagstaff, K.M. (2020) The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Re-search, 178, Article ID: 104787.
https://doi.org/10.1016/j.antiviral.2020.104787
|
[9]
|
Wulan, W.N., Heydet, D., Walker, E.J., Gahan, M.E. and Ghildyal, R. (2015) Nucleocytoplasmic Transport of Nucleocapsid Proteins of Enveloped RNA Viruses. Frontiers in Microbiology, 6, Article 553.
https://doi.org/10.3389/fmicb.2015.00553
|
[10]
|
Hiscox, J.A., Wurm, T., Wilson, L., Britton, P., Cavanagh, D. and Brooks, G. (2001) The Coronavirus Infectious Bronchitis Virus Nucleoprotein Localizes to the Nucleolus. Journal of Virology, 75, 506-512.
https://doi.org/10.1128/JVI.75.1.506-512.2001
|
[11]
|
Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S.A., Palese, P. and Baric, R.S. (2007) Severe Acute Respiratory Syndrome Coronavirus ORF6 Antagonizes STAT1 Function by Sequestering Nuclear Import Factors on the Rough Endoplasmic Reticulum/Golgi Membrane. Journal of Virology, 81, 9812-9824.
https://doi.org/10.1128/JVI.01012-07
|
[12]
|
Mittal, N. and Mittal, R. (2021) Inhaled Route and An-ti-Inflammatory Action of Ivermectin: Do They Hold Promise in Fighting against COVID-19? Medical Hypotheses, 146, Article ID: 110364.
https://doi.org/10.1016/j.mehy.2020.110364
|
[13]
|
Sen Gupta, P.S., Biswal, S., Panda, S.K., Ray, A.K. and Rana, M.K. (2020) Binding Mechanism and Structural Insights into the Identified Protein Target of Covid-19 with in-Vitro Effective Drug Ivermectin. Journal of Biomolecular Structure and Dynamics, 1-10. https://doi.org/10.26434/chemrxiv.12463946
|
[14]
|
Wagstaff, K.M., Rawlinson, S.M., Hearps, A.C. and Jans, D.A. (2011) An AlphaScreen®-Based Assay for High-Throughput Screening for Specific Inhibitors of Nuclear Import. Journal of Biomolecular Screening, 16, 192-200.
https://doi.org/10.1177/1087057110390360
|
[15]
|
Heidary, F. and Gharebaghi, R. (2020) Ivermectin: A Sys-tematic Review from Antiviral Effects to COVID-19 Complementary Regimen. The Journal of Antibiotics, 73, 593-602. https://doi.org/10.1038/s41429-020-0336-z
|
[16]
|
Low, Z.Y., Yip, A.J.W. and Lal, S.K. (2022) Re-positioning Ivermectin for Covid-19 Treatment: Molecular Mechanisms of Action against SARS-CoV-2 Replication. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1868, Article ID: 166294. https://doi.org/10.1016/j.bbadis.2021.166294
|
[17]
|
Hellwig, M.D. and Maia, A. (2021) A COVID-19 Prophy-laxis? Lower Incidence Associated with Prophylactic Administration of Ivermectin. International Journal of Anti-microbial Agents, 57, Article ID: 106248.
https://doi.org/10.1016/j.ijantimicag.2020.106248
|
[18]
|
Bernigaud, C., Guillemot, D., Ahmed-Belkacem, A., Grimaldi-Bensouda, L., Lespine, A., Berry, F., Softic, L., Chenost, C., Do-Pham, G., Giraudeau, B., et al. (2021) Oral Ivermectin for a Scabies Outbreak in a Long-Term Care Facility: Potential Value in Preventing COVID-19 and Associated Mortality. British Journal of Dermatology, 184, 1207-1209.
https://doi.org/10.1111/bjd.19821
|
[19]
|
Vora, A., Arora, V.K., Behera, D. and Tripathy, S.K. (2020) White Paper on Ivermectin as a Potential Therapy for COVID-19. Indian Journal of Tuberculosis, 67, 448-451. https://doi.org/10.1016/j.ijtb.2020.07.031
|
[20]
|
Bryant, A., Lawrie, T.A., Dowswell, T., Fordham, E.J., Mitch-ell, S., Hill, S.R. and Tham, T.C. (2021) Ivermectin for Prevention and Treatment of COVID-19 Infection: A Sys-tematic Review, Meta-Analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460.
https://doi.org/10.1097/MJT.0000000000001442
|
[21]
|
Hazan, S., Dave, S., Gunaratne, A.W., Dolai, S., Clancy, R.L., McCullough, P.A. and Borody, T.J. (2022) Effectiveness of Ivermectin-Based Multidrug Therapy in Severely Hypoxic, Ambulatory COVID-19 Patients. Future Microbiology, 17, 339-350. https://doi.org/10.2217/fmb-2022-0014
|
[22]
|
DiNicolantonio, J.J., Barroso, J. and McCarty, M. (2020) Iver-mectin May Be a Clinically Useful Anti-Inflammatory Agent for Late-Stage COVID-19. Open Heart, 7, e001350. https://doi.org/10.1136/openhrt-2020-001350
|
[23]
|
Gupta, D., Sahoo, A.K. and Singh, A. (2020) Ivermectin: Potential Candidate for the Treatment of Covid 19. The Brazilian Journal of Infectious Diseases, 24, 369-371. https://doi.org/10.1016/j.bjid.2020.06.002
|
[24]
|
Kerr, L., Cadegiani, F.A., Baldi, F., Lobo, R.B., Assagra, W.L.O., Proenca, F.C., Kory, P., Hibberd, J.A. and Chamie-Quintero, J.J. (2022) Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. Cureus, 14, e21272. https://doi.org/10.7759/cureus.c61
|
[25]
|
Reis, G., Silva, E., Silva, D.C.M., Thabane, L., Milagres, A.C., Ferreira, T.S., Dos Santos, C.V.Q., Campos, V.H.S., Nogueira, A.M.R., de Almeida, A., et al. (2022) Effect of Early Treatment with Ivermectin among Patients with Covid-19. New England Journal of Medicine, 386, 1721-1731. https://doi.org/10.1056/NEJMoa2115869
|
[26]
|
Lim, S.C.L., Hor, C.P., Tay, K.H., Mat Jelani, A., Tan, W.H., Ker, H.B., Chow, T.S., Zaid, M., Cheah, W.K., Lim, H.H., et al. (2022) Efficacy of Ivermectin Treatment on Disease Progression among Adults With Mild to Moderate COVID-19 and Comorbidities: The I-TECH Ran-domized Clinical Trial. JAMA Internal Medicine, 182, 426-435.
https://doi.org/10.1001/jamainternmed.2022.0189
|
[27]
|
Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M.C., Ojeda Fernandez, M.L., Alvisi, M.F., De Simone, I., Rulli, E., Nobili, A., Casalini, G., et al. (2022) High-Dose Ivermectin for Early Treatment of COVID-19 (COVER Study): A Randomised, Double-Blind, Multicentre, Phase II, Dose-Finding, Proof-of-Concept Clinical Trial. International Journal of Antimicrobial Agents, 59, Article ID: 106516. https://doi.org/10.1016/j.ijantimicag.2021.106516
|
[28]
|
Ozer, M., Goksu, S.Y., Conception, R., Ulker, E., Balderas, R.M., Mahdi, M., Manning, Z., To, K., Effendi, M., Anandakrishnan, R., et al. (2022) Effectiveness and Safety of Ivermectin in COVID-19 Patients: A Prospective Study at A Safety-Net Hospital. Journal of Medical Vi-rology, 94, 1473-1480. https://doi.org/10.1002/jmv.27469
|
[29]
|
Roman, Y.M., Burela, P.A., Pasupuleti, V., Piscoya, A., Vidal, J.E. and Hernandez, A.V. (2022) Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Infectious Diseases, 74, 1022-1029. https://doi.org/10.1093/cid/ciab591
|
[30]
|
Popp, M., Stegemann, M., Metzendorf, M.I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N. and Weibel, S. (2021) Ivermectin for Preventing and Treating COVID-19. Cochrane Database of Systematic Reviews, 7, Article ID: CD015017.
https://doi.org/10.1002/14651858.CD015017
|
[31]
|
Johnson-Arbor, K. (2022) Ivermectin: A Mini-Review. Clinical Toxicology, 60, 571-575.
https://doi.org/10.1080/15563650.2022.2043338
|
[32]
|
Camprubi, D., Almuedo-Riera, A., Marti-Soler, H., So-riano, A., Hurtado, J.C., Subira, C., Grau-Pujol, B., Krolewiecki, A. and Munoz, J. (2020) Lack of Efficacy of Standard Doses of Ivermectin in Severe COVID-19 Patients. PLOS ONE, 15, e0242184. https://doi.org/10.1371/journal.pone.0242184
|
[33]
|
Sen Gupta, P.S. and Rana, M.K. (2020) Ivermectin, Fa-motidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19. ACS Phar-macology & Translational Science, 3, 1037-1038.
https://doi.org/10.1021/acsptsci.0c00140
|
[34]
|
Schmith, V.D., Zhou, J.J. and Lohmer, L.R.L. (2020) The Ap-proved Dose of Ivermectin Alone Is Not the Ideal Dose for the Treatment of COVID-19. Clinical Pharmacology & Therapeutics, 108, 762-765.
https://doi.org/10.1002/cpt.1889
|
[35]
|
Solomon, S. (2020) FDA Letter to Stakeholders: Do Not Use Ivermectin Intended for Animals as Treatment for COVID-19 in Humans.
https://www.fda.gov/animal-veterinary/product-safety-information/fda-letter-stakeholders-do-not-use-ivermectin-intended-animals-treatment-covid-19-humans
|
[36]
|
World Health Organization (2021) WHO Advises That Iver-mectin Only Be Used to Treat COVID-19 within Clinical Trials. World Health Organization, Geneva.
|
[37]
|
Merck Statement on Ivermectin Use during the COVID-19 Pandemic. Merck.
https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic
|